Preeclampsia Emerging as a Novel Risk Factor for Cardiovascular Disease in the Offspring.
Preeclampsia Emerging as a Novel Risk Factor for Cardiovascular Disease in the Offspring.
复制标题
DOI:
10.2174/1573396316666191224092405
复制
发表时间:
2020
影响因子:
2
通讯作者:
Dimitriou G
中科院分区:
文献类型:
--
作者:
Karatza AA;Dimitriou G
Preeclampsia is a pregnancy specific disorder which affects 2%-8% of all gestations and is associated with high maternal, fetal and neonatal morbidity and mortality worldwide. There is no “cure” for the disease except for early delivery of the fetus and placenta, however leaving preeclampsia a long term health risk both for mothers and infants. The aim of the study is to review currently available information linking preclampsia to long-term cardiovascular complications in infants and children. Currently, there is evidence of predisposition to cardiovascular disease, and a higher incidence of cardiovascular risk factors among children born to preeclamptic mothers. Both in experimental models and human epidemiological studies it is now clear that the infants of pregnancies complicated by preeclampsia have an increased risk of developing high blood pressure and double the risk of stroke in later life. Preeclampsia is consistently associated with higher blood pressure and body mass index as early as 4–10 years of age. Also there is some evidence of higher cardiovascular risk in adults exposed to maternal hypertensive disorders of pregnancy. It seems that preeclampsia has an impact on the cardiovascular system independent of preterm birth and is associated with endothelial dysfunction, increased carotid intima media thickness and reductions in cardiac function that cannot be accounted for by prematurity alone. Taking into consideration the currently available evidence, it can now be suggested that preeclampsia is linked to adverse effects on the cardiometabolic health of the infant. Understanding the relationship between preeclampsia and cardiovascular disease will allow for implementation of early interventions to prevent or delay the onset of adverse events in this high risk population.
登录
查看更多内容
影响因子:
8.3
作者:
Lazdam, Merzaka;de la Horra, Arancha;Leeson, Paul
通讯作者:
Leeson, Paul
DOI:
10.1042/cs20110627
发表时间:
2012-07
期刊:
Clinical science (London, England : 1979)
影响因子:
--
作者:
Davis EF;Newton L;Lewandowski AJ;Lazdam M;Kelly BA;Kyriakou T;Leeson P
通讯作者:
Leeson P
影响因子:
8
作者:
通讯作者:
--
影响因子:
39.3
作者:
Piepoli, Massimo F.;Hoes, Arno W.;Verschuren, W. M. Monique
通讯作者:
Verschuren, W. M. Monique
影响因子:
7.2
作者:
Rice, Madeline Murguia;Landon, Mark B.;Blackwell, Sean C.
通讯作者:
Blackwell, Sean C.